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of CAP; however, BIPM would be effective for the initial treatment
of CAP in the elderly patients with chronic respiratory diseases.
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ella abortus
.F.E.M. Alawad
Animal Resources Research corporation, Central vet.Research
ab.(CVRL) -Soba, Khartoum, Sudan
Background: Brucellosis disease is a contagious, zoonotic,
ntreatable in animals and could treated in human with a lot of
ifﬁculties.
Treatment of Brucella in animal is economically not useful and
nsafe, where as there are different regimen of human brucellosis
reatment such as doxycycline 100mg/day and rifampin 600–900
g/day, both drugs are to given for 6 weeks. So the treatment is
akes long time and may reveal some complications. So application
f medicinal plants treatment is very valuable resources for new
gents against antibiotic-resistant Bacterial strains.
Moringa is a high value medicinal plant distributed in many
ountries of the tropics and subtropics. It has an impressive range
f medicinal uses with high nutritional values. Different parts of
his plant contain a proﬁle of important minerals, and are a good
ource of protein and vitamins.
The objective of this study is to invistigate the antimicrobial
ctivities ofMoringa oleifera leaves, roots and seeds in vitro against
rucella abortus strains.
Methods:Moringa oliefera leaves, roots and seeds extractswere
repared bymethanolicmethodbymixing 3g of the plant and10ml
ethanol.
The tested Brucella was propagated and harvested to from a
uspension adjusted to MacFarland standard turbidity number 0.5.
Sensitivity to Moringa extract was detected by disc-diffusion
ethod and the culture medium used was serum dextrose agar.
All extracts were tested in different dilutions so as to detect
he minimal bacterial concentration (MBC), these dilutions ranged
rom 3-300mg/ml which diluted with the extracted diluents and
ispensed on the suitable discs diameters.
three Brucella strains were used, B.abortus S19, B.abortus S 544
nd B.abortus ﬁeld strain isolated from cattle. Antibiotic discs were
lso used as control.
Results: Moringa leaves, roots and seeds showed an inhibitory
one in the three used Brucella abortus strains.
The inhibitory zones varied according to concentration of the
xtract as well as the type of strain and the speciﬁc part of the
lant.
Roots showed the largest inhibitory zone, then seeds and lastly
eaves. Moreover the reference strains B.abortus S19 and S 544
howed a larger zone than the ﬁeld strain.
Conclusion: Brucellosis treatment remains a major public
ealth concern. Moringa oleifera had anti-Brucella activity needs
ore trails of extraction methods and further investigations.
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Biapenem for community-acquired pneumonia in elderly
patients
S. Abe ∗, M. Sato, M. Nishiwaki, T. Nemoto, K. Yamauchi, S. Inoue,
Y. Shibata, I. Kubota
Yamagata University Hospital, Yamagata, Japan
Background: Pneumonia is one of the most common diseases
in elderly patients. Carbapenems are recommended for the treat-
ment of severe pneumonia in the Japanese Respiratory Society
Guidelines for the management of community-acquired pneumo-
nia (CAP) or hospital-acquired pneumonia (HAP). In general, the
use of carbapenems should be controlled from the point of view of
appropriate use of antibiotics, because they have a broad spectrum
of antimicrobial activity. Biapenem (BIPM) is one of the carbapen-
ems that was developed in Japan. The aim of this study is to
evaluate clinical efﬁcacies of BIPM for the treatment of CAP in
elderly patients.
Methods: A total of 52 elderly patients (40 men and 12 women)
were eligible for this study if they were 65 years or older, and had
administered to Yamagata University Hospital or the afﬁliated hos-
pitals in Yamagata due to CAP. The mean age of the 52 patients
was 82.6 years. The patients were excluded from this study if they
had any of the following: atypical pneumonia (e.g. Mycoplasma,
Legionella) or Mycobacterium infections (e.g. M. tuberculosis, M.
avium complex); severe heart failure, renal failure, or liver fail-
ure; malignant diseases. BIPM (600 mg b.i.d. or 900 mg t.i.d.) were
administered for 3 to 15 days to the eligible patients with informed
consents. BIPM was assessed to be clinically effective for the treat-
ment of CAP if 3 or more of the following criteria were improved:
symptoms; consolidates on chest X-ray; peripheral blood leuko-
cytes and C-reactive protein (CRP); bacterial culture of sputum or
blood.
Results: BIPM was effective in 36 of total 52 elderly patients
with CAP (69.2%). Furthermore, BIPM was effective in 10 of 11
elderly patients with CAP (90.9%) with previous diagnosis of
chronic obstructive pulmonary disease (COPD), bronchial asthma,
bronchiectasis, or pulmonary ﬁbrosis. No remarkable differences
in the efﬁcacies of BIPM in age of patients, severity of CAP, or total
daily dose of BIPM.
Conclusion: BIPM is not generally used in the empiric therapy
